Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1 results about "Bimolecular fluorescence complementation" patented technology

Bimolecular fluorescence complementation (also known as BiFC) is a technology typically used to validate protein interactions. It is based on the association of fluorescent protein fragments that are attached to components of the same macromolecular complex. Proteins that are postulated to interact are fused to unfolded complementary fragments of a fluorescent reporter protein and expressed in live cells. Interaction of these proteins will bring the fluorescent fragments within proximity, allowing the reporter protein to reform in its native three-dimensional structure and emit its fluorescent signal. This fluorescent signal can be detected and located within the cell using an inverted fluorescence microscope that allows imaging of fluorescence in cells. In addition, the intensity of the fluorescence emitted is proportional to the strength of the interaction, with stronger levels of fluorescence indicating close or direct interactions and lower fluorescence levels suggesting interaction within a complex. Therefore, through the visualisation and analysis of the intensity and distribution of fluorescence in these cells, one can identify both the location and interaction partners of proteins of interest.

CEA detection kit based on bimolecular fluorescence complementation technology, preparation method and use method thereof

InactiveCN108387736ALower requirementHigh detection sensitivityBiological testingAnti-CEA AntibodyFluorescent protein
The invention provides a CEA diagnosis kit based on a bimolecular fluorescence complementation technology, wherein the kit comprises an anti-CEA antibody conjugated fluorescent protein N-terminal fragment and an anti-CEA antibody conjugated fluorescent protein C-terminal fragment. The invention further discloses a preparation method of the CEA diagnosis kit, wherein the preparation method comprises: preparation of an anti-CEA antibody conjugated fluorescent protein N-terminal fragment, and preparation of an anti-CEA antibody conjugated fluorescent protein C-terminal fragment. The invention further discloses a use method the kit. According to the present invention, the kit has advantages of simple operation, no cleaning, high precision, high accuracy and the like, is conveniently suitable for clinical detection, can increase the accuracy of the diagnosis of tumors in the monitoring of tumors, and has great market value.
Owner:NANJING TZONE BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products